Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials
about
Molecular Imaging of Biomarkers in Breast CancerStrategies for modern biomarker and drug development in oncology.Is there a role of synovial biopsy in drug development?Evaluation of surrogate tissues as indicators of drug activity in a melanoma skin modelPlasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.Molecular analysis of circulating tumour cells-biology and biomarkers.Developing biomarker-specific end points in lung cancer clinical trials.Impact of phosphoproteomics in the translation of kinase-targeted therapies.Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma.Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer.Plucked human hair shafts and biomolecular medical research.Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
P2860
Q26772870-3ABE1E0D-8EEA-474C-9A98-B796DD1E7871Q30590270-24FC0130-8EB9-4856-A8A9-1B160BBE0F78Q35994130-4DAC24E0-06D0-4D6C-87A3-6A3BF31F04D6Q37148914-1AB1E036-6F9B-4193-B6C2-BEBF4E022123Q37660266-41611652-01D2-43E8-846B-E287AF3A5687Q38180320-BFD23B89-957A-40CD-95A9-D40B79C3F14CQ38297892-3F62F9A3-4ED1-40DE-AA58-499D27ED81D5Q38989188-A7EF0995-973B-4230-8B3F-C3BCC0133AD6Q38996431-374C9429-F555-4C06-BDFB-F53B8E23BD2CQ41503593-750CC29C-33DE-4CEC-9FB6-077F761331E7Q42282892-D6F3CE90-1353-47AA-BE7F-466B4EC66293Q50325731-63B9D943-1C36-45D5-99B1-C8C4085C3FC4Q51333483-DF65BC34-EF30-4540-995A-B4EC49BE7A05Q57298266-ACBDF4BE-2753-46ED-A075-30D8B4639B3E
P2860
Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Tissue-based approaches to stu ...... phase oncology clinical trials
@ast
Tissue-based approaches to stu ...... phase oncology clinical trials
@en
type
label
Tissue-based approaches to stu ...... phase oncology clinical trials
@ast
Tissue-based approaches to stu ...... phase oncology clinical trials
@en
prefLabel
Tissue-based approaches to stu ...... phase oncology clinical trials
@ast
Tissue-based approaches to stu ...... phase oncology clinical trials
@en
P2093
P2860
P921
P1433
P1476
Tissue-based approaches to stu ...... phase oncology clinical trials
@en
P2093
Joo Ern Ang
Udai Banerji
P2860
P304
P356
10.2174/138945012803530062
P5008
P577
2012-11-01T00:00:00Z